Clinical trial LUMINOSITY
Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
Cancers | |
---|---|
Organ | Lung |
Trial status | Trial open for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 2 |
Academic trial | Non |
Sponsor | AbbVie |
EudraCT Identifier | 2018-001772-38 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03539536 |
Last update |